A strong transdisciplinary team of doctors at Haukeland University Hospital has started to conduct a clinical study of the treatment. By the end of 2016 the study was halfway in phase 1, and the results so far show that the treatment causes few side effects and is well tolerated by the patients. Haukeland is the first hospital in the world to test the treatment fully, and a total of 18 patients with prostate cancer will participate in the study.
The preliminary results are promising, and the treatment has been well tolerated by the patients in the clinical study.
If the results from the clinical study proves to be successful, the treatment also can be used to cure other types of cancer.
BTO is the largest shareholder in Alden Cancer Therapy II, and we have contributed with business development, finance, legal assistance, patenting and communication.
The project has received verification funding from the FORNY2020 program at the Norwegian Research Council, as well as donations from several companies and individuals.
